中國國藥新冠疫苗獲世衛(wèi)組織緊急使用認(rèn)證，世衛(wèi)組織：建議不設(shè)定接種年齡上限

Sinopharm's new crown vaccine has been certified by the WHO for emergency use. WHO: It is recommended not to set an upper limit for vaccination age

 

當(dāng)?shù)貢r(shí)間7日下午，世界衛(wèi)生組織宣布，由中國醫(yī)藥集團(tuán)、北京生物制品研究所研發(fā)的 新冠滅活疫苗 正式通過世衛(wèi)組織緊急使用認(rèn)證，成為第6種獲得世衛(wèi)組織安全性、有效性和質(zhì)量驗(yàn)證的新冠疫苗。世衛(wèi)專家表示，中國國藥新冠疫苗安全有效，其預(yù)防重癥和住院的有效率可達(dá)79%。

On the afternoon of the 7th local time, the World Health Organization announced that the new crown inactivated vaccine developed by China National Pharmaceutical Group and Beijing Institute of Biological Products has officially passed the WHO emergency use certification, becoming the sixth type to obtain the safety, effectiveness and safety of the WHO. Quality-proven new crown vaccine. WHO experts said that China's Sinopharm's new crown vaccine is safe and effective, and its effective rate of preventing severe illness and hospitalization can reach 79%.

根據(jù)世衛(wèi)組織發(fā)布的臨時(shí)建議，18歲以上成年人可接種兩劑中國國藥新冠疫苗，間隔時(shí)間為三至四周；世衛(wèi)組織還建議不設(shè)定接種年齡上限，因?yàn)槌醪綌?shù)據(jù)顯示該疫苗對(duì)老年人也有保護(hù)作用。

According to the temporary recommendations issued by the WHO, adults over 18 years of age can receive two doses of the Chinese new crown vaccine, with an interval of three to four weeks; WHO also recommends not setting an upper limit for vaccination age because preliminary data shows that the vaccine is effective for the elderly. People also have a protective effect.

世衛(wèi)組織在聲明中指出，中國國藥新冠疫苗易于儲(chǔ)存的特點(diǎn)使其非常適用于資源匱乏的環(huán)境，它也是第一款攜帶疫苗瓶監(jiān)測器的疫苗，疫苗瓶上的小標(biāo)簽會(huì)因疫苗受熱而改變顏色，便于衛(wèi)生工作者判斷疫苗是否安全可用。

The WHO pointed out in the statement that the easy storage of China's Sinopharm Covid-19 vaccine makes it very suitable for resource-poor environments. It is also the first vaccine to carry a vaccine vial monitor. The small label on the vaccine vial will cause the vaccine to become heated. Change the color so that health workers can judge whether the vaccine is safe and available.

此前，世衛(wèi)組織已向5種新冠疫苗頒發(fā)緊急使用認(rèn)證，分別是美國輝瑞制藥有限公司和德國生物新技術(shù)公司聯(lián)合研發(fā)的新冠疫苗、英國阿斯利康制藥公司和牛津大學(xué)聯(lián)合研發(fā)的兩個(gè)版本阿斯利康疫苗、美國強(qiáng)生公司旗下楊森制藥公司研發(fā)的新冠疫苗以及美國莫德納公司研發(fā)的新冠疫苗。

Prior to this, the WHO has issued emergency use certifications to five new crown vaccines, which are the new crown vaccine jointly developed by Pfizer Pharmaceuticals Co., Ltd. of the United States and the German Biotech Company, and two versions jointly developed by AstraZeneca Pharmaceuticals of the United Kingdom and the University of Oxford. AstraZeneca vaccine, the new crown vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, and the new crown vaccine developed by Modena of the United States.

 

From website: https://baijiahao.baidu.com/